Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 300.50
Ask: 311.50
Change: 0.00 (0.00%)
Spread: 11.00 (3.661%)
Open: 300.00
High: 300.00
Low: 300.00
Prev. Close: 300.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Initiation of Phase II Collaborative Study

10 Jul 2012 07:00

RNS Number : 2649H
Oxford Biomedica PLC
10 July 2012
 

 

 

 

 

 

 

Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer

 

-- First patient treated at Cardiff University, Wales (UK) --

 

Oxford, UK - 10 July 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC). The study will be funded by Cardiff University, with some funding awarded by Cancer Research Wales, and Oxford BioMedica will provide TroVax®. The trial is supported by the Experimental Cancer Medicine Centre (ECMC), Cardiff.

 

The randomised, open-label Phase II study, entitled "TaCTiCC" (TroVax® and Cyclophosphamide Treatment in Colorectal Cancer), builds on four previous Phase I/II trials conducted by Oxford BioMedica where TroVax® was given to patients with CRC, in addition to research into CRC undertaken by Dr Andrew Godkin and Dr Awen Gallimore at Cardiff University, Wales. Led by Dr Andrew Godkin, the study will enrol up to 54 patients with inoperable metastatic CRC. The study will evaluate whether TroVax®, administered alone or in combination with cyclophosphamide, is effective in the treatment of CRC. The study will assess anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival.

 

Colorectal cancer is the second most common cause of cancer mortality in the UK with an estimated 16,000 deaths per year (source: Cancer Research UK, 2010). TroVax® is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours. It is well documented that low doses of cyclophosphamide can augment immune responses by decreasing the numbers of a class of blood cell called a "regulatory T cell". By combining TroVax® with cyclophosphamide, this study will determine whether the combination approach results in stronger immune responses against 5T4 compared to patients treated with TroVax® alone.

 

Commenting on the collaboration, Stuart Naylor, Chief Scientific Officer at Oxford BioMedica, said: "We believe TroVax® holds great promise in the treatment of colorectal cancer and very much look forward to working with our colleagues at Cardiff University. This important study builds on pioneering work undertaken by Dr Godkin and his team and we are pleased to be able to support the transition into Phase II clinical development."

 

Dr Andrew Godkin, Principal Investigator at Cardiff University, commented: "We are very excited in Cardiff to be starting this study. It is a truly translational study in as much as preliminary data have been generated from a series of experiments which started over 10 years ago. There has been a tremendous amount of support from various parties to drive this forward, the logistic hurdles are crossed and we are now ready to go."

 

- Ends -

 

For further information, please contact:

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary Clark/Sarah Macleod/Claire Dickinson M:Communications

 

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.

 

2. TroVax®

TroVax® is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours. The product comprises a modified vaccinia virus Ankara (MVA) vector, encoding the 5T4 antigen. Vaccinia viruses are commonly used as delivery systems for the development of antigen-specific vaccines. Results from 10 previous clinical trials in colorectal, renal and prostate cancer have shown that TroVax® is safe and well tolerated in over 500 patients; can be administered in combination with various other treatments and show clear indication of efficacy. Approximately 90% of patients treated with TroVax® mounted an anti-cancer immune response to the 5T4 antigen. TroVax® is currently in Phase II development for hormone refractory prostate cancer.

 

3. The School of Medicine, Cardiff University

Cardiff University's School of Medicine is recognised as a significant contributor to healthcare in Wales, a major provider of professional staff for the National Health Service and an international centre of excellence for research delivering substantial health benefits locally and internationally. The School of Medicine is based at the Heath Park Campus, a site it shares the University Hospital of Wales, the third largest university hospital in the UK. It has an all-Wales role, contributing greatly to promoting, enhancing and protecting the nation's health in partnership with the National Health Service (NHS) in Wales. The medical curriculum followed at the School enables students to acquire and apply knowledge, skills, judgement and attitudes appropriate to delivering a high standard of professional care. The School is an international leader in basic and clinically applied research activities and has been instrumental in establishing and running many important national research initiatives including the Wales Gene Park, Wales Cancer Bank, the Cardiff Institute for Tissue Engineering and Repair and the Healing Foundation UK Centre for Burns Research.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABKCDNABKDCOK
Date   Source Headline
13th Dec 20217:00 amRNSOxford Biomedica Signs Agreement with Arcellx
1st Dec 20219:49 amRNSTotal Voting Rights
1st Nov 202110:08 amRNSLong Term Incentive Plan Option Grant
1st Nov 202110:02 amRNSTotal Voting Rights
19th Oct 20217:00 amRNSBoehringer Ingelheim Exercises Option
1st Oct 20219:51 amRNSTotal Voting Rights
29th Sep 20215:54 pmRNSHolding(s) in Company
29th Sep 20215:36 pmRNSDirectors Dealings / Market Share Purchases
28th Sep 20214:48 pmRNSHolding(s) in Company
28th Sep 202110:01 amRNSTotal Voting Rights
22nd Sep 20217:38 amRNSStrategic investment by Serum Life Sciences
22nd Sep 20217:00 amRNSInterim Results
1st Sep 202110:48 amRNSTotal Voting Rights
1st Sep 20217:00 amRNSNotice of Interim Results
3rd Aug 20212:20 pmRNSLTIP Option Grant
2nd Aug 202111:16 amRNSTotal Voting Rights
15th Jul 20217:00 amRNSNon-Executive Director Appointment
6th Jul 20213:10 pmRNSDirector/PDMR Shareholding
1st Jul 202111:35 amRNSBlock listing Return
1st Jul 202110:43 amRNSTotal Voting Rights
24th Jun 20211:05 pmRNSDirectors Dealings / Market Share Purchases
9th Jun 202110:36 amRNSHolding(s) in Company
8th Jun 20212:32 pmRNSGrant of options
1st Jun 202110:13 amRNSTotal Voting Rights
28th May 20217:00 amEQSOxford Biomedica (OXB): Driving innovation in a thriving CGT industry
28th May 20217:00 amRNSBlock Listing Application
28th May 20217:00 amRNSResult of AGM
27th May 20217:00 amRNSBoard Change
25th May 20219:21 amRNSDirector/PDMR Shareholding
21st May 202112:46 pmRNSPDMR Dealing
20th May 202111:42 amRNSPDMR Dealings
18th May 20217:00 amRNSOxford Biomedica upgrades financial guidance
10th May 202110:54 amRNSHolding(s) in Company
4th May 202110:29 amRNSTotal Voting Rights
4th May 202110:27 amRNSHoldings in Company
27th Apr 20212:40 pmRNS2020 Annual report and Accounts & AGM Notification
26th Apr 202112:32 pmRNSHolding(s) in Company
15th Apr 20217:00 amRNSFull year results
6th Apr 20217:00 amRNSOXB signs Agreement with Boehringer Ingelheim
1st Apr 202111:04 amRNSTotal Voting Rights
30th Mar 202110:22 amRNSHolding(s) in Company
19th Mar 20217:01 amRNSUpdate on Sanofi Collaboration & License Agreement
15th Mar 202110:03 amRNSNotice of Preliminary Results
1st Mar 20219:36 amRNSTotal Voting Rights
26th Feb 202110:46 amRNSPDMR Dealings / Market Share sale
5th Feb 20211:22 pmRNSHoldings in Company
3rd Feb 20217:00 amRNSBoard Changes
1st Feb 20219:47 amRNSTotal Voting Rights
4th Jan 20212:09 pmRNSBlock Listing Return
4th Jan 20211:41 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.